Global Diphtheria, Pertussis, and Tetanus (DTaP) Vaccine Market is Expected to Reach USD 5.07 Billion by 2026 : Fior Markets
January 16, 2020 21:00 ET
|
Fior Markets
New Jersey, NJ, Jan. 16, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, the global diphtheria, pertussis, and tetanus (DTaP) vaccine market is expected to grow from USD 2.97...
Tetanus Toxoid Vaccine Market To Reach USD 6.46 Billion By 2026 | Reports And Data
April 15, 2019 13:04 ET
|
Reports And Data
The rise in the number of reported cases of tetanus and diphtheria in the developing countries will be the major factor influencing the market growth. Market Size – USD 4.35 Billion in 2018, Market...
DTaP Vaccine Market To Reach USD 5.00 Billion By 2026 | Reports And Data
April 15, 2019 12:14 ET
|
Reports And Data
Growing demand for DTaP vaccines to prevent the occurrence of diseases such as diphtheria, tetanus, and pertussis is a significant factor expected to stimulate market growth. Market Size – USD 2.88...
ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Key Milestones Including Positive Phase 1b Clinical Study Data
July 05, 2017 09:00 ET
|
ILiAD Biotechnologies, LLC
NEW YORK, July 05, 2017 (GLOBE NEWSWIRE) -- ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotechnology company, today announced promising results from its Phase 1b pertussis vaccine clinical...
Great Basin Scientific Receives FDA 510(k) Clearance for Bordetella Direct Test
April 03, 2017 16:00 ET
|
Great Basin Scientific, Inc.
SALT LAKE CITY, April 03, 2017 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:GBSN), a molecular diagnostics company, has received U.S. Food & Drug Administration (FDA) clearance for...
Great Basin Scientific Completes Clinical Trial, Submits FDA 510(k) Application for Bordetella Direct Test
February 01, 2017 07:00 ET
|
Great Basin Scientific, Inc.
SALT LAKE CITY, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:GBSN), a molecular diagnostics company, today announced the completion of the clinical trial and 510(k)...
Phase 1b Clinical Trial of BPZE1 Pertussis Vaccine Completes Enrollment of Randomized Study Groups
February 19, 2016 09:55 ET
|
ILiAD Biotechnologies, LLC
NEW YORK, Feb. 19, 2016 (GLOBE NEWSWIRE) -- ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotechnology company, announced today that enrollment has been completed for three randomized groups...